Get the Stockscreener App
4.88
3.83%
0.18
After Hours:
4.91
0.03
+0.61%
Zentalis Pharmaceuticals Inc stock is traded at $4.88, with a volume of 1.40M.
It is up +3.83% in the last 24 hours and up +35.56% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.70
Open:
$4.71
24h Volume:
1.40M
Relative Volume:
0.64
Market Cap:
$347.39M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-2.8081
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
+9.42%
1M Performance:
+35.56%
6M Performance:
+30.48%
1Y Performance:
+256.20%
1-Day Range:
$4.29
$4.91
1-Week Range:
$4.29
$4.94
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.88 | 334.58M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech - ad-hoc-news.de
Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance - ad-hoc-news.de
June 2026 Penny Stocks With Promising Potential - Sahm
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
Zentalis Pharmaceuticals Surges 14%: Biotech Stock Breaks Above Key Support ZoneBearish Pattern Stocks - dars.gov.et
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2000 Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000E Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL) - TradingView
Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals Inc (ZNTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zentalis Pharmaceuticals (ZNTL) Edges Higher as Biotech Sector Sees Mixed SentimentDividend Arbitrage - dars.gov.et
ZNTL Should I Buy - Intellectia AI
Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan
Zentalis Pharmaceuticals Inc (ZNTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Chart - ChartMill
Number of shareholders of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals (ZNTL) Consolidates Near Support as Biotech Sector Awaits CatalystsFloat Adjusted Cap - newsline.com
Zentalis Pharmaceuticals Insider Sellers Vindicated After 10% Drop - simplywall.st
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
ZNTL: Azenosertib shows promise in PROC, with strong efficacy and future combination plans underway - TradingView
Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Zentalis grants 191,000 stock options to new hires under Nasdaq inducement rule. - Pluang
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Expands Board, Appoints New Director - TipRanks
Zentalis strengthens commercial leadership with appointments of Shannon Campbell to board of directors and Sarah Kelly as SVP of commercial strategy - marketscreener.com
Zentalis adds board member, commercial executive ahead of trial data - Investing.com
Zentalis adds board member, commercial executive ahead of trial data By Investing.com - Investing.com Canada
Zentalis (ZNTL) director Shannon Campbell receives 114,200-share RSU award - Stock Titan
Zentalis Pharmaceuticals (ZNTL) expands board, awards RSUs to new director - Stock Titan
Zentalis (ZNTL) director Campbell Shannon files routine Form 3 insider report - Stock Titan
Zentalis Strengthens Commercial Leadership with - GlobeNewswire
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - Yahoo Finance
ZNTL - Finviz
ZNTL: Azenosertib shows promising efficacy and safety in ovarian cancer, with pivotal data expected this year - TradingView
Zentalis Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):